Price Alert

Amicus Therapeutics Inc. (FOLD)

NASDAQ: FOLD · Real-Time Price · USD

8.24

-0.08 (-0.96%)

At close: Sep 26, 2025, 3:59 PM

8.24

0.00%

After-hours: Sep 26, 2025, 04:28 PM EDT

Amicus Therapeutics Statistics

Share Statistics

Amicus Therapeutics has 308.24M shares outstanding. The number of shares has increased by 3.82% in one year.

Shares Outstanding	308.24M
Shares Change (YoY)	3.82%
Shares Change (QoQ)	0.22%
Owned by Institutions (%)	99.69%
Shares Floating	288.21M
Failed to Deliver (FTD) Shares	10
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 20.93M, so 6.8% of the outstanding shares have been sold short.

Short Interest	20.93M
Short % of Shares Out	6.8%
Short % of Float	6.84%
Short Ratio (days to cover)	5.47

Valuation Ratios

The PE ratio is -51.1 and the forward PE ratio is 27.73. Amicus Therapeutics's PEG ratio is 0.79.

PE Ratio	-51.1
Forward PE	27.73
PS Ratio	5.43
Forward PS	3.3
PB Ratio	14.78
P/FCF Ratio	-76.57
PEG Ratio	0.79

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Amicus Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.39, with a Debt / Equity ratio of 2.29.

Current Ratio	3.39
Quick Ratio	2.6
Debt / Equity	2.29
Debt / EBITDA	15.1
Debt / FCF	-11.85
Interest Coverage	0.5

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$1.06M
Profits Per Employee	$-112.44K
Employee Count	499
Asset Turnover	0.67
Inventory Turnover	0.45

Taxes

Income Tax	27.35M
Effective Tax Rate	-95.11%

Stock Price Statistics

The stock price has increased by -23.06% in the last 52 weeks. The beta is 0.55, so Amicus Therapeutics's price volatility has been higher than the market average.

Beta	0.55
52-Week Price Change	-23.06%
50-Day Moving Average	7.32
200-Day Moving Average	7.76
Relative Strength Index (RSI)	58.63
Average Volume (20 Days)	4,440,087

Income Statement

In the last 12 months, Amicus Therapeutics had revenue of 528.29M and earned -56.11M in profits. Earnings per share was -0.18.

Revenue	528.29M
Gross Profit	475.35M
Operating Income	24.88M
Net Income	-56.11M
EBITDA	29.39M
EBIT	20.84M
Earnings Per Share (EPS)	-0.18

Full Income Statement

Balance Sheet

The company has 213.75M in cash and 443.64M in debt, giving a net cash position of -229.89M.

Cash & Cash Equivalents	213.75M
Total Debt	443.64M
Net Cash	-229.89M
Retained Earnings	-2.74B
Total Assets	815.3M
Working Capital	370.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -33.89M and capital expenditures -3.55M, giving a free cash flow of -37.44M.

Operating Cash Flow	-33.89M
Capital Expenditures	-3.55M
Free Cash Flow	-37.44M
FCF Per Share	-0.12

Full Cash Flow Statement

Margins

Gross margin is 89.98%, with operating and profit margins of 4.71% and -10.62%.

Gross Margin	89.98%
Operating Margin	4.71%
Pretax Margin	-5.44%
Profit Margin	-10.62%
EBITDA Margin	5.56%
EBIT Margin	4.71%
FCF Margin	-7.09%

Dividends & Yields

FOLD does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for FOLD is $16, which is 94.2% higher than the current price. The consensus rating is "Buy".

Price Target	$16
Price Target Difference	94.2%
Analyst Consensus	Buy
Analyst Count	9

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-1.05
Piotroski F-Score	3